2026

  • Shi J, Hu H, Ung COL*. Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. Regen Ther. 2026 Mar 18;32:101102. doi: 10.1016/j.reth.2026.101102. PMID: 41890351; PMCID: PMC13015211.
  • Chen S, Chen Y, Zhang Y, Yao G, Cai H, Chen X*, Hu Y*. Mapping the TNFR2-targeting antibody patent landscape: Insights from macro trends to structural signatures. Hum Vaccin Immunother. 2026 Dec;22(1):2639177. doi: 10.1080/21645515.2026.2639177. Epub 2026 Mar 9. PMID: 41797544; PMCID: PMC12973476.
  • Tan X, Luo Q, Ge Y, Deng N, Jin P, Song M, Ung COL, Chen M, Hu H*. Decoding the Mechanisms of Hepatocellular Carcinoma Cancer Stem Cells and Identifying Potential Therapeutic Strategies Based on Single-cell Omics. Cancer Genomics Proteomics. 2026 Mar-Apr;23(2):281-299. doi: 10.21873/cgp.20577. PMID: 41771574; PMCID: PMC12951371.
  • Liu J, Hu H, Ung COL*, Song M*. Facilitators and barriers to the decision-making of breast cancer screening in female residents in Mainland China: a systematic literature review. BMC Public Health. 2026 Jan 28;26(1):682. doi: 10.1186/s12889-026-26233-7. PMID: 41606534; PMCID: PMC12922332.
  • Li PF, Du YY, Zheng SL, Qian ZM, Zhou JL, Huang ZS*, Hu YJ*. Citri Grandis Exocarpium with medicine and food homology: A review regarding its potential anti-obesity effects and future applications. J Ethnopharmacol. 2026 Apr 24;361:121224. doi: 10.1016/j.jep.2026.121224. Epub 2026 Jan 14. PMID: 41544729.
  • Wang A, Luo Q, Tan X, Yao Y, Peng X, Luo H*, Hu Y*. Development and application of artificial intelligence in traditional Chinese medicine research and development. Chin Med. 2026 Jan 8;21(1):17. doi: 10.1186/s13020-025-01288-7. PMID: 41508020; PMCID: PMC12781431.

2025

  • Cai H, Zhang T, Hu Y*. Global landscape of PROTAC: Perspectives from patents, drug pipelines, clinical trials, and licensing transactions. Eur J Med Chem. 2025 Dec 5;299:118055. doi: 10.1016/j.ejmech.2025.118055. Epub 2025 Aug 8. PMID: 40812067.
  • Ge Y, Li J, Ming C, Ung COL, Lai Y, Hu H*. Proteomic and Transcriptomic Analyses Define Molecular Subtypes, Identify Biomarkers, and Suggest Potential Therapeutic Agent for Early-Stage HBV-Related Hepatocellular Carcinoma. J Proteome Res. 2025 Dec 5;24(12):6238-6251. doi: 10.1021/acs.jproteome.5c00828. Epub 2025 Nov 4. PMID: 41187230.
  • Peng Y, Lyu L, Chen S, Ning B, Li C, Wu CY*, Hu Y*. Monoclonal antibody formulations: a quantitative analysis of marketed products and patents. MAbs. 2025 Dec;17(1):2580696. doi: 10.1080/19420862.2025.2580696. Epub 2025 Oct 30. PMID: 41163552; PMCID: PMC12578304.
  • Xue Y, Song M, Ung COL, Hu H*. Using unsupervised machine learning methods to cluster cardio-metabolic profile of the middle-aged and elderly Chinese with general and central obesity. BMC Cardiovasc Disord. 2025 Oct 27;25(1):772. doi: 10.1186/s12872-025-05157-x. PMID: 41146029; PMCID: PMC12557893.
  • Wong CI, Zheng Y, Chen Y, Tsai YT, Ung COL, Song M*, Lei C*. Viral Epidemiology and Etiology of Acute Respiratory Infections Among Hospitalized Pediatric Patients in Macao Across the Pre-, Peri-, and Post-COVID-19 Era. J Med Virol. 2025 Nov;97(11):e70664. doi: 10.1002/jmv.70664. PMID: 41128620.
  • Zheng Y, Tang PK, Zhao Y, Song M, Hu H, Ung COL*. Qualitative study of stakeholder perspectives on dementia policy implementation in Macao: progress, challenges and future directions. BMJ Open. 2025 Oct 9;15(10):e102523. doi: 10.1136/bmjopen-2025-102523. PMID: 41067772; PMCID: PMC12517005.
  • Chen X, Shi J, Xue Y, Lai Y, Song M, Ung COL, Hu H*. Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control. Glob Health Res Policy. 2025 Oct 2;10(1):50. doi: 10.1186/s41256-025-00450-w. PMID: 41035085; PMCID: PMC12490094.
  • Wang C, Lyu L, Liu D*, Hu Y*. An updated patent review of small molecule glucagon receptor antagonists (2020-2024). Expert Opin Ther Pat. 2025 Nov;35(11):1169-1183. doi: 10.1080/13543776.2025.2559928. Epub 2025 Sep 21. PMID: 40968011.
  • Yang J, Li Y, Li Y, Song M, Hu H, Ung COL*. Assessing the efficacy and safety of traditional Chinese medicine for cancer-related fatigue in lung cancer patients: A comprehensive meta-analysis of randomized controlled trials. Pharmacological Research – Modern Chinese Medicine. Volume 17, 2025, 100683. doi: 10.1016/j.prmcm.2025.100683.
  • Lin Q, Ung COL, Lai Y, Hu H*, Jakovljevic M*. Critical Analysis of Markov Modeling for the Economic Evaluation of Obesity Interventions: A Systematic Review. Risk Manag Healthc Policy. 2025 Jun 28;18:2169-2187. doi: 10.2147/RMHP.S528064. PMID: 40606035; PMCID: PMC12219201.
  • Shi J, Yang J, Zheng Y, Wong PHH, Hu H, Ung COL*. The clinical quality management system of advanced therapy medicinal products in the hospital setting: A scoping review. Mol Ther Methods Clin Dev. 2025 May 8;33(2):101485. doi: 10.1016/j.omtm.2025.101485. PMID: 40547477; PMCID: PMC12179598.
  • Wong PHH, Chau CI, Hu H, Ung COL*. Evaluation of a competency-based CPD programme for pharmacists on asthma care: a feasibility study. Saudi Pharm J. 2025 Jun 4;33(3):14. doi: 10.1007/s44446-025-00021-7. PMID: 40465048; PMCID: PMC12137867.
  • Xue Y, Song M, Yu H, Chen X, Ung COL*, Hu H*. Implementation of Clinical Services for Adults with Obesity in Different Health Systems: A Scoping Review and Causal Loop Diagram. Diabetes Metab Syndr Obes. 2025 May 22;18:1695-1709. doi: 10.2147/DMSO.S501149. PMID: 40433462; PMCID: PMC12106910.
  • Song M, Zhou H, Yang Z, Lai Y, Ung COL*, Hu H*. Development and Validation of an Approach to Assessing Clinical Relevance of Potential Drug-Drug Interactions Inducing Rare but Serious Adverse Events. Clin Transl Sci. 2025 May;18(5):e70253. doi: 10.1111/cts.70253. PMID: 40390272; PMCID: PMC12089653.
  • Xia M, Xue Y, Zhu L, Chen X, Ung COL, Han S, Lai Y*, Hu H*. Advancing human-use experience for real-world evidence for the registration of traditional Chinese medicine products in China. BMC Complement Med Ther. 2025 May 14;25(1):174. doi: 10.1186/s12906-025-04906-x. PMID: 40369511; PMCID: PMC12077040.
  • Zheng L, Xue Y, Chen X, Ung COL, Hu H*. Application of system dynamics approach in developing health interventions to strengthen health systems to combat obesity: a systematic literature review and critical analysis. BMC Public Health. 2025 Apr 29;25(1):1580. doi: 10.1186/s12889-025-22821-1. PMID: 40301836; PMCID: PMC12039072.
  • Li Y, Yang J, Li Y, Hu H, Ung COL*. Efficacy and safety of acupuncture for weight management: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2025 Jun;90:103171. doi: 10.1016/j.ctim.2025.103171. Epub 2025 Apr 4. PMID: 40189109.
  • Pang Y, Li J, Hu H, Ung COL*. Genetic associations of prostate cancer in China: a systematic review. BMC Cancer. 2025 Apr 3;25(1):604. doi: 10.1186/s12885-025-13830-9. PMID: 40181298; PMCID: PMC11966891.
  • Xue Y, Song M, Chen X, Ruan Z, Zou H, Lai Y, Yao D, Ung COL*, Hu H*. Consolidating International Care Models and Clinical Services for Adult Obesity. Curr Obes Rep. 2025 Mar 28;14(1):26. doi: 10.1007/s13679-025-00621-3. PMID: 40153156.
  • Hu Y, Zou H, Shen Y, Ni Q, Li Y, Zhang H, Chen X, Ung COL, Hu H*, Mu Y*. Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise. Diabetes Ther. 2025 May;16(5):915-929. doi: 10.1007/s13300-025-01716-9. Epub 2025 Mar 19. PMID: 40106226; PMCID: PMC12006588.
  • Lin G, Lai M, Chau CI, Hu H, Ung COL*. Exploring the knowledge, attitude, and practice of community pharmacists regarding pediatric asthma management in Guangdong Province, China: a cross-sectional survey study. BMC Med Educ. 2025 Feb 22;25(1):291. doi: 10.1186/s12909-025-06885-6. PMID: 39987180; PMCID: PMC11846212.
  • Yin S, Huang S, Xue P, Xu Z, Lian Z, Ye C, Ma S, Liu M, Hu Y*, Lu P*, Li C*. Generative artificial intelligence (GAI) usage guidelines for scholarly publishing: a cross-sectional study of medical journals. BMC Med. 2025 Feb 11;23(1):77. doi: 10.1186/s12916-025-03899-1. PMID: 39934830; PMCID: PMC11816781.
  • Chen X, Cai K, Xue Y, Ung COL, Hu H*, Jakovljevic M*. Using system dynamics modeling approach to strengthen health systems to combat cancer: a systematic literature review. J Med Econ. 2025 Dec;28(1):168-185. doi: 10.1080/13696998.2025.2450168. Epub 2025 Jan 10. PMID: 39764688.
  • Shi J, Chen X, Hu H, Ung COL*. The role of hospital pharmacists in supporting the appropriate and safe use of CGT/ATMPs: a scoping review of current insights. BMC Health Serv Res. 2025 Jan 9;25(1):52. doi: 10.1186/s12913-024-12026-4. PMID: 39789612; PMCID: PMC11721208.
  • Zou H, Lai Y, Chen X, Ung COL, Hu H*. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma. Ther Adv Gastroenterol. 2025 Jan 2;18:17562848241310314. doi: 10.1177/17562848241310314. PMID: 39758963; PMCID: PMC11694292.

2024

  • Lai Y, Ho Q, Wang Y, Liang X, Xue Y, Ung COL, Li M, Yao D, Liu B, Bian Y*, Xie Z*, Hu H*. Challenges and strategies of developing internet hospital: Combining qualitative interview and documentary research. Digit Health. 2024 Dec 26;10:20552076241310075. doi: 10.1177/20552076241310075. PMID: 39741982; PMCID: PMC11686650.
  • Hu Y, Chen X, Zou H, Zhang H, Ni Q, Li Y, Ung COL, Hu H*, Mu Y*. Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study. Adv Ther. 2025 Feb;42(2):904-917. doi: 10.1007/s12325-024-03082-7. Epub 2024 Dec 16. PMID: 39680313.
  • Han Y, Wang M, Chen Y, Ouyang D, Zheng Y*, Hu Y*. Profiling patent compounds in lipid nanoparticle formulations of siRNA. Mol Ther Nucleic Acids. 2024 Oct 18;35(4):102362. doi: 10.1016/j.omtn.2024.102362. PMID: 39554995; PMCID: PMC11565460.
  • Deng N, Yan Z, Wang S, Song M*, Hu H*. Utilization of Immune Checkpoint Inhibitors in Human Epidermal Growth Factor Receptor 2-Negative, Advanced Metastatic, or Unresectable Gastric Cancer Under All Combined Positive Score Grading: Evaluation of Efficacy Based on Individual Patient Data Reconstruction and Secondary Analyses. Clin Ther. 2025 Feb;47(2):148-157. doi: 10.1016/j.clinthera.2024.11.014. Epub 2024 Dec 5. PMID: 39643452.
  • Ruan Z, Chen X, Song M, Jia R, Luo H, Ung COL, Hu H*. Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China. Diabetes Metab Syndr Obes. 2024 Oct 5;17:3657-3666. doi: 10.2147/DMSO.S483065. PMID: 39386037; PMCID: PMC11463179.
  • Lei PK, Liu Z, Ung COL, Hu H*. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis. BMC Gastroenterol. 2024 Sep 30;24(1):331. doi: 10.1186/s12876-024-03414-5. PMID: 39350091; PMCID: PMC11440749.
  • Zhang CR, Zhang DY, Gao J, Cao ZM, Hu YJ*. Exploring the mechanisms of Yuanhu Zhitong oral liquid for primary dysmenorrhea through network pharmacology, molecular docking, and molecular dynamics simulation. Reprod Dev Med. 2024;8(3):138–150. doi: 10.1097/RD9.0000000000000097
  • Zhang XZ, Wong PHH, Lai KS, Yang B, Song M, Li J, Ung COL*. Effectiveness of COVID-19 Vaccination against Severe Symptoms and Death Among Geriatric Inpatients: A Retrospective Cohort Study in Macao. Vaccines (Basel). 2024 Aug 21;12(8):933. doi: 10.3390/vaccines12080933. PMID: 39204056; PMCID: PMC11359226.
  • Zheng Y, Tang PK, Hu H, Ung COL*. Patterns of self-medication and intention to seek pharmacist guidance among older adults during the COVID-19 pandemic in Macao: a cross-sectional study. BMC Public Health. 2024 Jul 31;24(1):2066. doi: 10.1186/s12889-024-19453-2. PMID: 39085834; PMCID: PMC11293033.
  • Zou H, Ge Y, Chen W, Yao D, Oi Lam Ung C, Lai Y*, Hu H*. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors. Int Immunopharmacol. 2024 May 10;132:111947. doi: 10.1016/j.intimp.2024.111947. Epub 2024 Mar 29. PMID: 38552296.
  • Shi J, Chen X, Hu H, Ung COL*. The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards. Cytotherapy. 2024 Aug;26(8):954-966. doi: 10.1016/j.jcyt.2024.04.070. Epub 2024 Apr 27. PMID: 38739075.
  • Lyu L., Feng Y., Huang B. Xu RH*, Hu Y*. Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials. Nat Biotechnol. 2024 Apr 17;42, 563–569). doi: 10.1038/s41587-024-02196-1. PMID: 38632441.
  • Zhang D, Lyu L, Han S, Xu J, Hu G, Zhao Q, Hu Y*. Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials. Int Immunopharmacol. 2024 Jan 5;126:111273. doi: 10.1016/j.intimp.2023.111273. Epub 2023 Dec 4. PMID: 38041957.

2023

  • Yang J, Yang J, Hu YJ*. Characteristics of clinical trials of new oncology drugs approved in China. Cancer. 2024 Mar 1;130(5):671-682. doi: 10.1002/cncr.35106. Epub 2023 Nov 20. PMID: 37985356.
  • Shi J, Chen X, Hu H, Ung COL*. Benchmarking Drug Regulatory Systems for Capacity Building: An Integrative Review of Tools, Practice, and Recommendations. Int J Health Policy Manag. 2023;12:8100. doi: 10.34172/ijhpm.2023.8100. Epub 2023 Oct 16. PMID: 38618782; PMCID: PMC10699822.
  • Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H*. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. PLoS One. 2023 Oct 5;18(10):e0292239. doi: 10.1371/journal.pone.0292239. PMID: 37796814; PMCID: PMC10553296.
  • Shi J, Chen X, Hu H, Ung COL*. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557. PMID: 37213606; PMCID: PMC10192700.
  • 時君楠, 陳獻文, 胡豪, 吳靄琳*. 推進藥品監管體系和監管能力現代化：藥品監管能力基準評估的國際經驗[J]. 中國食品藥品監管. 2023.04(231):14-33. doi: 10.3969/j.issn.1673-5390.2023.04.002